Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

GATM locus does not replicate in rhabdomyolysis study

Abstract

Arising from L. M. Mangravite et al. Nature 502, 377–380 (2013); doi:10.1038/nature12508

All HMG-CoA reductase inhibitors (statins) can cause muscle injury ranging from asymptomatic elevations in creatine kinase levels to severe muscle breakdown (rhabdomyolysis) leading to kidney failure and death1, and the genetic variants responsible for this uncommon adverse drug reaction remain largely undiscovered. Mangravite et al. reported a new locus in the gene GATM (rs9806699) that was associated with a decreased risk of muscle injury in two case-control studies of myopathy (odds ratio, 0.60)2. In a larger case-control study of statin-related rhabdomyolysis, a more severe form of muscle injury, we were unable to replicate this finding. This failure to replicate raises questions about the role of GATM in statin-related muscle injury. There is a Reply to this Brief Communication Arising by Mangravite, L. M. et al. Nature 513, http://dx.doi.org/10.1038/nature13630 (2014).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Thompson, P. D., Clarkson, P. & Karas, R. H. Statin-associated myopathy. J. Am. Med. Assoc. 289, 1681–1690 (2003)

    Article  CAS  Google Scholar 

  2. Mangravite, L. M., Engelhardt, B. E., Stephens, M. & Krauss, R. M. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature 502, 377–380 (2013)

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  3. Marciante, K. D. et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet. Genomics 21, 280–288 (2011)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Floyd, J. S. et al. A screening study of drug–drug interactions in cerivastatin users: an adverse effect of clopidogrel. Clin. Pharmacol. Ther. 91, 896–904 (2012)

    Article  CAS  PubMed  Google Scholar 

  5. Staffa, J. A., Chang, J. & Green, L. Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. 346, 539–540 (2002)

    Article  PubMed  Google Scholar 

  6. Carr, D. F. et al. GATM gene variants and statin myopathy risk. Nature 513, http://dx.doi.org/10.1038/nature13628 (2014)

  7. Tamraz, B. et al. OATP1B1-related drug–drug and drug–gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis. Pharmacogenet. Genomics 23, 355–364 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kameyama, Y., Yamashita, K., Kobayashi, K., Hosokawa, M. & Chiba, K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics 15, 513–522 (2005)

    Article  CAS  PubMed  Google Scholar 

  9. SEARCH Collaborative Group et al. SLCO1B1 variants and statin-induced myopathy–a genomewide study. N. Engl. J. Med. 359, 789–799 (2008)

    Article  Google Scholar 

  10. Voora, D. et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 54, 1609–1616 (2009)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Linde, R., Peng, L., Desai, M. & Feldman, D. The role of vitamin D and SLCO1B1*5 gene polymorphism in statin-associated myalgias. Dermatoendocrinol. 2, 77–84 (2010)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Carr, D. F. et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin. Pharmacol. Ther. 94, 695–701 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Fried, L. P. et al. The Cardiovascular Health Study: design and rationale. Ann. Epidemiol. 1, 263–276 (1991)

    Article  CAS  PubMed  Google Scholar 

  14. Psaty, B. M. et al. Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. The Cardiovascular Health Study Collaborative Research Group. J. Clin. Epidemiol. 45, 683–692 (1992)

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

J.C.B. and J.S.F. carried out the analyses. B.M.P. obtained the funding for this work. J.S.F., F.C.B., J.A.B., S.R.H., K.R. and B.M.P. contributed to the design of the analyses and the drafting and revision of the manuscript.

Corresponding author

Correspondence to James S. Floyd.

Ethics declarations

Competing interests

B.M.P. serves on the data and safety monitoring board (DSMB) for a clinical trial of a device funded by the manufacturer (Zoll LifeCor).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Floyd, J., Bis, J., Brody, J. et al. GATM locus does not replicate in rhabdomyolysis study. Nature 513, E1–E3 (2014). https://doi.org/10.1038/nature13629

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature13629

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing